Search results for " Cutaneous"

showing 10 items of 172 documents

Decreased presence of Langerhans cells is a critical determinant for Indian Post kala-azar dermal leishmaniasis.

2015

Post kala-azar dermal leishmaniasis (PKDL) is the dermal sequel of visceral leishmaniasis (VL) and occurs after apparent cure or alongside with VL. It is confined to South Asia (India, Nepal and Bangladesh) and East Africa (mainly Sudan), the incidence being 5-10% and 50-60% respectively. In South Asia, as the transmission of VL is anthroponotic, PKDL patients are the proposed disease reservoir, thus assuming epidemiological significance, its eradication being linked to the control of leishmaniasis. In the absence of an animal model and its low incidence, factors contributing towards the immunopathogenesis of PKDL remain an open-ended, yet pertinent question. This study delineated the lesio…

Disease reservoirIndiaLeishmaniasis CutaneousCell CountDermatologyBiochemistryImmune systemImmunopathologyparasitic diseasesmedicineInterleukin-12 Receptor beta 1 SubunitHumansRNA MessengerMolecular BiologyPost-kala-azar dermal leishmaniasisGranulomabusiness.industryCD68MacrophagesLeishmaniasismedicine.diseaseInterleukin-10Visceral leishmaniasisGranulomaLangerhans CellsImmunologyLeishmaniasis VisceralbusinessExperimental dermatology
researchProduct

Controlled transdermal iontophoresis by ion-exchange fiber

2000

The objective of this study was to assess the transdermal delivery of drugs using iontophoresis with cation- and anion-exchange fibers as controlled drug delivery vehicles. Complexation of charged model drugs with the ion-exchange fibers was studied as a method to achieve controlled transdermal drug delivery. Drug release from the cation-exchange fiber into a physiological saline was dependent on the lipophilicity of the drug. The release rates of lipophilic tacrine and propranolol were significantly slower than that of hydrophilic nadolol. Permeation of tacrine across the skin was directly related to the iontophoretic current density and drug concentration used. Anion-exchange fiber was te…

DrugChemical PhenomenaSkin Absorptionmedia_common.quotation_subjectPharmaceutical Science02 engineering and technologyIn Vitro TechniquesPharmacologyAdministration Cutaneous030226 pharmacology & pharmacyDosage form03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHumansFiberElectrodesSodium salicylateTransdermalmedia_commonMineral FibersActive ingredientChromatographyIontophoresisChemistry PhysicalIontophoresisModels Theoretical021001 nanoscience & nanotechnologyIon ExchangechemistryDrug deliveryTacrine0210 nano-technologyAlgorithmsJournal of Controlled Release
researchProduct

Transdermal therapy and diagnosis by iontophoresis

1997

Iontophoresis, the use of an electric current to drive charged molecules across the skin, has the potential to expand the feasible range of drugs for transdermal administration significantly. This method of delivery is being examined carefully with respect to higher-molecular-weight therapeutics (in particular, peptides and small proteins), which cannot be absorbed following oral administration and for which, at this time, an invasive injection remains the only option. In addition, the procedure of so-called 'reverse' iontophoresis would appear to represent a truly noninvasive approach for diagnostic monitoring of blood chemistry.

Drugddc:615Skin Diseases/diagnosis/therapyPeptides/administration & dosageIontophoresisbusiness.industrymedia_common.quotation_subjectBiotechnology/trendsBioengineeringIontophoresis/methodsIontophoresisPharmacologyAdministration CutaneousDiagnostic monitoringSkin DiseasesBlood chemistryOral administrationHumansMedicinePeptidesbusinessBiotechnologymedia_commonTransdermalTrends in Biotechnology
researchProduct

Safety of the current drug treatments for vitiligo

2020

Introduction: Vitiligo is an acquired depigmenting skin disorder adversely affecting the patient's quality of life. Despite the presence of several treatment modalities, ranging from medical to physical to surgical options, none is curative. Each modality has its own drawbacks and side effects. Thus, the treatment modality needs to be tailored for each individual patient taking into consideration the disease characteristics and also its efficacy and safety to obtain a favorable risk-benefit ratio.Areas covered: This review highlights the different treatment modalities utilized in vitiligo up until 4 November 2019 along with their adverse effects and contraindications, if any.Expert opinion:…

Drugmedicine.medical_specialtymedia_common.quotation_subjectVitiligoVitiligo030204 cardiovascular system & hematologyAdministration Cutaneous03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Adrenal Cortex HormonesmedicineHumansEffective treatmentPharmacology (medical)Intensive care medicineAdverse effectmedia_commonBiological ProductsModality (human–computer interaction)business.industryGeneral Medicinemedicine.diseaseTreatment modality030220 oncology & carcinogenesisQuality of LifeDisease characteristicsDermatologic AgentsbusinessExpert Opinion on Drug Safety
researchProduct

Mangiferin glycethosomes as a new potential adjuvant for the treatment of psoriasis

2020

[EN] Mangiferin, a natural compound isolated from Mangifera indica L, was incorporated in glycerosomes, ethosomes and alternatively in glycerol-ethanol phospholipid vesicles (glycethosomes). Actually, only glycethosomes were able to stably incorporate the mangiferin that was loaded at increasing concentrations (2, 4, 6, 8 mg/mL). The morphology, size distribution, rheological properties, surface charge and entrapment efficiency of prepared vesicles were deeply measured. All vesicles were mainly spherical, oligolamellar, small in size (similar to 145 nm) and negatively charged (similar to-40 mV), as confirmed by cryo-TEM observation and dynamic laser light scattering measurements. The higher…

GlycerolAntioxidantDrug CompoundingXanthonesmedicine.medical_treatmentPharmaceutical Science02 engineering and technologyAdministration Cutaneous030226 pharmacology & pharmacyMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineIn vivoPhospholipid vesiclesGlycerolmedicineAnimalsHumansPsoriasisTissue DistributionMangiferinHydrogen peroxidePhospholipidsSkin permeationAdjuvants PharmaceuticDrug CarriersWound HealingMangiferaEthanolVesicle3T3 CellsHydrogen Peroxide021001 nanoscience & nanotechnologyIn vitroDisease Models AnimalchemistryBiophysicsMangiferinGlycethosomesTetradecanoylphorbol AcetateFemaleAntioxidantEpidermis0210 nano-technologyDrug carrierInternational Journal of Pharmaceutics
researchProduct

Gamma-delta T-cell lymphomas.

2009

Peripheral T-cell lymphomas (TCLs) are uncommon neoplasms, accounting for about 12% of all lymphoid tumors worldwide. TCLs in which gammadelta T-cell receptors are expressed (gammadelta TCLs) are extremely aggressive and rare (<1% of lymphoid neoplasms). gammadelta TCLs originate from gammadelta T cells, a small subset of peripheral T cells with direct antigen recognition capability acting at the interface between innate and adaptive immunity. Two distinct gammadelta TCL entities are recognized: hepatosplenic T-cell lymphoma (HSTL) and primary cutaneous gammadelta T-cell lymphoma (PCGD-TCL). HSTL is a well-characterized extranodal lymphoma that has a disguised onset, secondary to intrasinus…

Hepatosplenic T-cell lymphomaT cellGene Rearrangement delta-Chain T-Cell Antigen Receptorchemical and pharmacologic phenomenaprimary cutaneous gamma delta T-cell lymphomaImmune systemmedicineHumansGamma delta T cellLymphoma T-Cell CutaneouClinical Trials as Topicbusiness.industryGene Rearrangement gamma-Chain T-Cell Antigen Receptorgamma delta T-cell receptorMedicine (all)Peripheral T-cell lymphomaLymphoma T-Cell PeripheralReceptors Antigen T-Cell gamma-deltaGene rearrangementmedicine.diseaseAcquired immune systemLymphomaLymphoma T-Cell Cutaneousstomatognathic diseasesmedicine.anatomical_structurehepatosplenic T-cell lymphomaOncologyImmunologyBone marrowbusinessHuman
researchProduct

Secreted proteophosphoglycan of Leishmania mexicana amastigotes activates complement by triggering the mannan binding lectin pathway.

1997

Cutaneous lesions induced by infection of mice with the protozoan parasite, Leishmania mexicana, contain abundant amounts of a high molecular mass proteophosphoglycan (PPG), which is secreted by the amastigote stage residing in phagolysosomes of macrophages and can then be released into the tissue upon rupture of the infected cells. Amastigote PPG forms sausage-shaped but soluble particles and belongs to a novel class of serine-rich proteins that are extensively O-glycosylated by phosphooligosaccharides capped by mannooligosaccharides. The purified molecule is shown here to efficiently activate complement (C) and deplete hemolytic activity of normal serum and may prevent the opsonization of…

ImmunologyLeishmania mexicanaProtozoan ProteinsCollectinLeishmaniasis CutaneousLeishmania mexicanaMiceImmunology and AllergyAnimalsAmastigoteComplement ActivationMannan-binding lectinSerine proteaseMice KnockoutbiologyMacrophagesComplement C4Complement C3biology.organism_classificationCollectinsComplement systemAntibody opsonizationBiochemistryLectin pathwaybiology.proteinMice Inbred CBACalciumProteoglycansCarrier ProteinsEuropean journal of immunology
researchProduct

Impaired Th1 responses in mice deficient in Epstein-Barr virus-induced gene 3 and challenged with physiological doses of Leishmania major.

2005

Protection against Leishmania major is dependent on IL-12 release from L. major-infected dendritic cells (DC) that induce IFN-gamma-producing Th1/Tc1 cells. IL-27, a novel member of the IL-12 family, is a heterodimer composed of p28 and IL-12p40-related Epstein-Barr virus-induced gene 3 (EBI3), and was shown to be produced by DC. In this study, we utilized EBI3-deficient mice to investigate the role of IL-27 in leishmaniasis using physiological low-dose infections that mimic natural transmissions. Lesions in EBI3(-/-) mice were significantly larger between weeks 3 and 10 post infection, reaching up to approximately threefold increased lesion volumes compared to wild types. In parallel, derm…

ImmunologyPopulationCD11cLeishmaniasis CutaneousBiologyLesionMinor Histocompatibility AntigensMiceT-Lymphocyte SubsetsmedicineImmunology and AllergyAnimalsLeishmania majorRNA MessengerReceptors CytokineeducationLeishmania majoreducation.field_of_studyEBI3Dendritic cellDendritic CellsTh1 Cellsbiology.organism_classificationImmunologyInterleukin 12Lymphmedicine.symptomEuropean journal of immunology
researchProduct

Keratinocytes Determine Th1 Immunity during Early Experimental Leishmaniasis

2010

Experimental leishmaniasis is an excellent model system for analyzing Th1/Th2 differentiation. Resistance to Leishmania (L.) major depends on the development of a L. major specific Th1 response, while Th2 differentiation results in susceptibility. There is growing evidence that the microenvironment of the early affected tissue delivers the initial triggers for Th-cell differentiation. To analyze this we studied differential gene expression in infected skin of resistant and susceptible mice 16h after parasite inoculation. Employing microarray technology, bioinformatics, laser-microdissection and in-situ-hybridization we found that the epidermis was the major source of immunomodulatory mediat…

KeratinocytesCellular differentiationImmunology/Innate ImmunityInterleukin-1betaGene ExpressionInfectious Diseases/Skin InfectionsMiceT-Lymphocyte SubsetsLeishmania majorBiology (General)In Situ HybridizationOligonucleotide Array Sequence AnalysisSkinRegulation of gene expressionMice Inbred BALB CReverse Transcriptase Polymerase Chain ReactionCell DifferentiationImmunohistochemistryInterleukin-12MicrodissectionResearch ArticleQH301-705.5ImmunologyLeishmaniasis CutaneousBiologyMicrobiologyTh2 CellsImmune systemCutaneous leishmaniasisImmunology/Immunity to InfectionsVirologyGeneticsmedicineAnimalsDermatology/Skin InfectionsMolecular BiologyInterleukin 4Epidermis (botany)Interleukin-6Gene Expression ProfilingLasersTh1 CellsRC581-607medicine.diseasebiology.organism_classificationMice Inbred C57BLGene expression profilingDisease Models AnimalImmunology/Immune ResponseImmunologyOsteopontinParasitologyInterleukin-4Immunologic diseases. AllergyPLoS Pathogens
researchProduct

Development of novel diolein–niosomes for cutaneous delivery of tretinoin: Influence of formulation and in vitro assessment

2014

Abstract This work describes innovative niosomes, composed of diolein alone or in association with the hydrophilic penetration enhancer Labrasol ® , as carriers for cutaneous drug delivery. The model drug was tretinoin and conventional, and Labrasol ® containing liposomes was used as controls to evaluate the influence of vesicle composition and the role of Labrasol ® on vesicle physico-chemical properties and performance as skin delivery system. Vesicles, prepared by the thin film hydration technique, were characterized in terms of size distribution, morphology, zeta potential, structure, incorporation efficiency, and rheological properties. The influence of carrier composition on tretinoin…

KeratinocytesSurface PropertiesDrug CompoundingSkin AbsorptionPharmaceutical ScienceTretinoinHuman skinNanotechnologyIn Vitro TechniquesAdministration CutaneousGlyceridesDiglyceridesX-Ray DiffractionStratum corneummedicineZeta potentialHumansNiosomeParticle SizeCells CulturedSkinDrug CarriersLiposomeMicroscopy ConfocalChemistryBilayerVesicleEndocytosismedicine.anatomical_structureLiposomesDrug deliveryBiophysicsRheologyInternational Journal of Pharmaceutics
researchProduct